Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective study
X Pu, QZ Wang, L Liu, B Chen, K Li, Y Zhou… - Cancer …, 2023 - Wiley Online Library
Background Clinical evidence of immune checkpoint inhibitors combined with
antiangiogenic drugs in patients with advanced non‐small cell lung cancer (NSCLC) was …
antiangiogenic drugs in patients with advanced non‐small cell lung cancer (NSCLC) was …
Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study
X Pu, QZ Wang, L Liu, B Chen, K Li… - Cancer …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Clinical evidence of immune checkpoint inhibitors combined with
antiangiogenic drugs in patients with advanced non-small cell lung cancer (NSCLC) was …
antiangiogenic drugs in patients with advanced non-small cell lung cancer (NSCLC) was …
Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective study.
X Pu, QZ Wang, L Liu, B Chen, K Li, Y Zhou… - Cancer …, 2023 - search.ebscohost.com
Background: Clinical evidence of immune checkpoint inhibitors combined with
antiangiogenic drugs in patients with advanced non‐small cell lung cancer (NSCLC) was …
antiangiogenic drugs in patients with advanced non‐small cell lung cancer (NSCLC) was …
Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study
X Pu, QZ Wang, L Liu, B Chen, L Kang… - Cancer …, 2023 - search.proquest.com
Background Clinical evidence of immune checkpoint inhibitors combined with
antiangiogenic drugs in patients with advanced non-small cell lung cancer (NSCLC) was …
antiangiogenic drugs in patients with advanced non-small cell lung cancer (NSCLC) was …
[HTML][HTML] Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective study
X Pu, QZ Wang, L Liu, B Chen, K Li, Y Zhou… - Cancer …, 2023 - ncbi.nlm.nih.gov
Background Clinical evidence of immune checkpoint inhibitors combined with
antiangiogenic drugs in patients with advanced non‐small cell lung cancer (NSCLC) was …
antiangiogenic drugs in patients with advanced non‐small cell lung cancer (NSCLC) was …
Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study.
X Pu, Q Wang, L Liu, B Chen, K Li, Y Zhou… - Cancer …, 2022 - europepmc.org
Background Clinical evidence of immune checkpoint inhibitors combined with
antiangiogenic drugs in patients with advanced non-small cell lung cancer (NSCLC) was …
antiangiogenic drugs in patients with advanced non-small cell lung cancer (NSCLC) was …
Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study.
X Pu, Q Wang, L Liu, B Chen, K Li, Y Zhou… - Cancer …, 2022 - europepmc.org
Background Clinical evidence of immune checkpoint inhibitors combined with
antiangiogenic drugs in patients with advanced non-small cell lung cancer (NSCLC) was …
antiangiogenic drugs in patients with advanced non-small cell lung cancer (NSCLC) was …